Interferon-α-Induced Biologic Modifications in Patients with Chronic Myelogenous Leukemia
- 1 December 1994
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Journal of Interferon Research
- Vol. 14 (6), 349-355
- https://doi.org/10.1089/jir.1994.14.349
Abstract
Serum neopterin (Np), (β2-microglobulin (β2-M), and 2′,5′-adenylate (2′,5′A) levels and intracellular 2′,5′A and human Mx (Hu-Mx) protein synthesis were measured in 20–24 chronic myeloid leukemia patients before and during 1 year of IFN-α treatment and in a further 8–9 patients before and at the end of the first and second treatment weeks only. Univariate analysis showed that IFN-α increased Np and 2′,5′A serum levels and intracellular concentrations of 2′,5′A and Hu-Mx significantly from the end of the first week to month 12 of therapy. The biologic marker profiles were similar in cytogenetic responders and nonresponders, as well as in patients treated with IFN-α early (12 months standard chemotherapy). Further, there were no differences in the short-term (first 14 days) or long-term (during 12 month therapy) induction of the biologic markers irrespective of whether IFN-α2a or IFN-α2b, was given. Because multivariate analysis revealed no significant interactions between cytogenetic response, time to treatment, and type of IFN-α used, increments in intracellular 2′,5′A and Hu-Mx protein were similar at all study times for all factor combinations tested. Np levels varied significantly only during the first 14 therapy days; changes in serum 2′,5′A were never statistically significant. Discrepancies between univariate and multivariate analyses for the last two markers, with respect to intracellular 2′,5′A and Hu-Mx protein, may have been a result of the small number of observations for each factor combination, a less marked induction of these two molecules, and the diversity of their values in single patients.Keywords
This publication has 36 references indexed in Scilit:
- Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemiaAnnals of Hematology, 1993
- Double-Blind Randomized Phase I Study on the Clinical Tolerance and Biological Effects of Natural and Recombinant Interferon-βJournal of Interferon Research, 1992
- Biochemical and immunological responses of hairy cell leukemia patients to interferonβCancer Immunology, Immunotherapy, 1991
- Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumoursThe Lancet, 1990
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyThe New England Journal of Medicine, 1990
- Biochemical Host Response to Interferon-βJournal of Interferon Research, 1988
- Clinical and Biological Effects of Recombinant Interferon-β Administered Intravenously Daily in Phase I TrialJournal of Interferon Research, 1988
- INTERFERONS AND THEIR ACTIONSAnnual Review of Biochemistry, 1987
- Enhanced Level of Double-Stranded RNA-Dependent Protein Kinase in Peripheral Blood Mononuclear Cells of Patients with Viral InfectionsJournal of Interferon Research, 1986
- Effects of Interferon on Sensitive and Resistant L1210 Cell Lines.Journal of Interferon Research, 1981